Clinical investigation of anti-fungal strategies in patients under aggressive treatment of hematological malignancies

Clinical investigation of anti-fungal strategies in patients under aggressive treatment of hematological malignancies - AMSTE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000347

Enrollment

150

Registered

2012-07-10

Start date

2010-01-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z94.80 B44 C92 D46.9

Interventions

Group 1: anti fungal prophylaxis Group 2: empirical therapy if no response on antibiotics in case of fever Group 3: preemptive therapy in case of poritive galaktomanan or CT chest

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: allogeneic hämatopoetich cell transplantation Induktiontherapy acute leucemia consolidation therapy acute leucemia

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

Measure	Time frame
Incidence of breaktrough fungal infection after empirical, prophylactic and preemptive antimykotic therapy	—

Secondary

Measure	Time frame
costeffectiveness therapy and diagnostic of antifungal drugs	—

Countries

Germany

Contacts

Public ContactHartmut Bertz

Uniklinik Freiburg

hartmut.bertz@uniklinik-freiburg.de0761 270 33350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026